Products Categories
CAS No.: | 95734-82-0 |
---|---|
Name: | Nedaplatin |
Article Data: | 2 |
Molecular Structure: | |
Formula: | C2H8N2O3Pt |
Molecular Weight: | 303.177 |
Synonyms: | Platinum,diammine[hydroxyacetato(2-)-O1,O2]-,(SP-4-3)-;Acetic acid, hydroxy-, platinum complex;254S;Aqupla;NSC 375101; |
Boiling Point: | 265.6oC at 760 mmHg |
Flash Point: | 128.7oC |
Appearance: | Straw yellow powder |
PSA: | 42.01000 |
LogP: | 0.12010 |
The Nedaplatin is an organic compound with the formula C2H8N2O3Pt. The IUPAC name of this chemical is azanide; 2-hydroxyacetic acid; platinum(2+). With the CAS registry number 95734-82-0, it is also named as (Glycolato-O,O')diammineplatinum(II). The product's category is Anticancer Platinum Agent. Besides, it is a platinum compound which is used for cancer chemotherapy.
Physical properties about Nedaplatin are: (1)ACD/LogP: -1.05; (2)ACD/LogD (pH 5.5): -3.22; (3)ACD/LogD (pH 7.4): -4.63; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 3; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 2; (11)Polar Surface Area: 35.53 Å2; (12)Flash Point: 128.7 °C; (13)Enthalpy of Vaporization: 58.47 kJ/mol; (14)Boiling Point: 265.6 °C at 760 mmHg; (15)Vapour Pressure: 0.00125 mmHg at 25°C.
You can still convert the following datas into molecular structure:
(1)SMILES: [Pt+2].O=C(O)CO.[NH2-].[NH2-]
(2)InChI: InChI=1/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2
(3)InChIKey: KLNFSAOEKUDMFA-UHFFFAOYAW
(4)Std. InChI: InChI=1S/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2
(5)Std. InChIKey: KLNFSAOEKUDMFA-UHFFFAOYSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LDLo | intravenous | 4mg/kg (4mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 740, 1995. | |
mouse | LD50 | intravenous | 44100ug/kg (44.1mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 740, 1995. | |
rat | LDLo | intravenous | 20mg/kg (20mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION | Kiso to Rinsho. Clinical Report. Vol. 29, Pg. 3585, 1995. |